Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0006142 (breast cancer)
 160,383 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Among 3,528 BCDP-USC screenees, women who had breast cancer before entering the screening program (Group IA) or who had breast cancer detected during the program (Group IB) had a much higher chance of developing a breast cancer later (second primary) than those without any breast cancers (Group II, III, IV). With a median follow-up of seven years after the initial visit (1974-1976), the chances of developing a breast cancer during follow-up study are 24%, 7%, and 0.8% respectively. On the other hand, the chances of developing non-mammary malignancy are not too different between the various cohort groups (2.0-3.3%). Computer analysis of a selected Triad subgroups (487 screenees) also showed that the overall age-specific cancer incidences of our population are similar to that of the 1973-1977 SEER's data. When the relative frequency of specific site of 137 malignancies is concerned, we did see a few more cases of leukemia and melanoma than the SEER's data. However, the number of cases involved is small. Follow-up of all screenees will be continued, and this is only a preliminary report.
 ...
PMID:Subsequent mammary and other malignant neoplasms in participants of the Breast Cancer Detection Demonstration Project. 647 55

The Fragile Histidine Triad (FHIT) Gene, encompassing the FRA3B fragile site at chromosome 3p14.2, is a tumor suppressor gene involved in different tumor types. Abnormalities of the FHIT locus were found in many established cancer cell lines and tumors including breast cancer. In sporadic breast cancer, loss of heterozygosity within the FHIT gene has been observed at different frequencies and has been correlated with tumor progression. Aberrant FHIT transcripts have been reported in breast cancer. Furthermore, Fhit protein loss is correlated with prognosis. We summarized the research advances of FHIT genetic, epigenetic change and aberrant Fhit protein expression in breast cancer. Fhit protein may be a novel prognostic factor for breast cancer. FHIT gene therapy may potentially be clinically useful for treatment of breast cancer, suggesting further research involving FHIT introduction should be performed in breast cancer.
 ...
PMID:The Fragile Histidine Triad gene and breast cancer. 1211 13

FRA3B and FRA16D are the most sensitive common chromosomal fragile site loci in the human genome and two tumor suppressor genes FHIT (Fragile Histidine Triad) and WWOX (WW domain-containing oxidoreductase gene) map to this sites. The WWOX gene is composed of 9 exons and encodes a 46-kD protein that contains 414 amino acids. Loss of heterozygosity, homozygous deletions, and chromosomal translocations affecting WWOX has been reported in several types of cancer, including ovarian, esophageal, lung and stomach carcinoma, and multiple myeloma. The aim of this study was to determine the role of WWOX as a tumor suppressor gene in patients with breast cancer. Tumor and adjacent non-cancerous tissue samples were obtained from 81 patients with breast cancer. DNA was isolated from all tissue samples, and all exons and flanking intronic sequences of the WWOX gene were analyzed by PCR amplification and direct sequencing. We detected 14 different alterations in the coding sequence and one base substitution at the intron 6 splice site (+1 G-A). In addition to exonic and splice-site alterations, we detected 23 different alterations in the non-coding region of the gene. All coding region mutations identified in this study were in the exons between 4 and 9. We did not observe any alterations in exons 1-3. We conclude that mutations in critical region of the WWOX gene are frequent and may have an important role in breast carcinogenesis.
 ...
PMID:Genetic alterations of the WWOX gene in breast cancer. 2198 61